Repatha Cost in South Dakota 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Is the Retail Cash Price of Repatha in South Dakota?

The sticker price of Repatha at South Dakota retail pharmacies in 2026 runs approximately $580 per month for either dosing schedule: 140 mg every two weeks or 420 mg once monthly. That figure reflects the Amgen wholesale acquisition cost passed through most major chains, and paying cash without any assistance programs means bearing the full amount. For patients without insurance or with high-deductible plans, the number is prohibitive enough that many abandon therapy before cardiovascular benefit accrues.

Evolocumab is a fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). By blocking PCSK9, it prevents LDL receptor degradation and drives LDL-C down by roughly 59% from baseline, as measured in the landmark FOURIER trial [1]. The FDA granted Repatha approval in August 2015 [2], and its label covers adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy [2].

Prices at independent South Dakota pharmacies may vary by five to fifteen dollars from chain-store pricing, so calling ahead is worthwhile. GoodRx and similar discount aggregators occasionally surface prices between $520 and $575 at specific South Dakota zip codes, though those coupons are rarely stackable with insurance. The American College of Cardiology's 2022 consensus pathway recommends PCSK9 inhibitors for patients whose 10-year ASCVD risk exceeds 20% and whose LDL-C remains above 70 mg/dL despite maximally tolerated statin plus ezetimibe [3].

Does South Dakota Medicaid Cover Repatha in 2026?

South Dakota Medicaid does not cover Repatha for most enrollees in 2026. The state's fee-for-service formulary omits evolocumab, and managed-care contracts administered under South Dakota's Medicaid program have similarly excluded it based on cost-effectiveness thresholds. Patients enrolled in Medicaid should not assume that a prescriber's clinical justification alone will reveal coverage.

The Institute for Clinical and Economic Review (ICER) published an updated PCSK9 inhibitor assessment finding that evolocumab reaches cost-effectiveness thresholds only at prices well below the list price [4]. Several state Medicaid programs have cited that ICER analysis when declining to add PCSK9 inhibitors to their formularies. South Dakota's decision aligns with that pattern.

Medicaid patients in South Dakota who meet clinical criteria for evolocumab have three realistic paths. First, they can apply for Amgen's Repatha patient assistance program (Amgen Safety Net Foundation), which serves uninsured and underinsured patients earning up to 600% of the federal poverty level and can supply the drug at no cost [2]. Second, they can ask their prescriber to submit a formal prior authorization request; though approvals are rare, documented statin intolerance combined with LDL-C above 190 mg/dL and a confirmed FH diagnosis has occasionally cleared the bar on appeal. Third, compounded evolocumab through a state-licensed 503A pharmacy is legal in South Dakota and may be the most accessible cost path (detailed in the section below).

The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease states: "For patients with LDL-C levels persistently 70 mg/dL or higher... the addition of a PCSK9 inhibitor may be considered" [5]. That language documents medical necessity for appeal letters.

How Commercial Insurance Covers Repatha in South Dakota

Most South Dakota commercial insurance plans cover Repatha at tier 3 or tier 4, subject to prior authorization, step-therapy requirements, and sometimes a specialty pharmacy mandate. Before a plan will dispense even one pen, prescribers typically must document that the patient has tried and failed (or cannot tolerate) at least two statins plus ezetimibe.

Medica, Sanford Health Plan, and Wellmark Blue Cross Blue Shield operate plans in South Dakota with evolocumab on their specialty tier. Each plan's step-therapy requirement varies, but all three require documented LDL-C above 70 mg/dL on maximally tolerated statin therapy and an established ASCVD or FH diagnosis [3]. A 2022 analysis published in JAMA Cardiology found that PCSK9 inhibitor prior authorization denials occurred at a rate of 80% on first submission, with roughly 50% of those eventually reversed on appeal [6]. South Dakota patients should expect a similar pattern.

Employer-sponsored self-insured plans administered by third-party administrators (TPAs) based in South Dakota may follow different formularies. Checking with the plan's pharmacy benefits manager (PBM) directly is the only reliable way to confirm coverage terms before submitting a prescription.

Medicare Part D enrollees face separate rules. Evolocumab is covered by most Part D plans, though it lands on specialty tiers with cost-sharing that can reach $200 to $500 per month out of pocket before the catastrophic phase. The Inflation Reduction Act's $2,000 out-of-pocket cap for Part D, effective January 2025, materially reduces catastrophic-phase exposure for South Dakota Medicare enrollees on Repatha [7].

The Amgen Repatha Savings Card: How It Works in South Dakota

Commercially insured South Dakota patients who qualify for the Amgen Repatha savings card can pay as little as $0 per month, with a maximum savings of $3,500 per year. The card applies to the patient's portion of cost after insurance, so it does not help uninsured patients or those on government programs including Medicaid, Medicare, or CHIP.

Enrollment is completed online at Amgen's patient support portal or by calling 1-844-REPATHA. Eligibility requirements as of 2026 include: commercial insurance only, residency in the United States, and not enrolled in any federal or state healthcare program. The card auto-renews annually. If insurance denies the claim entirely, the savings card does not apply to the denied claim; a separate patient assistance program exists for those patients.

A 2021 study in the American Journal of Managed Care found that manufacturer copay cards reduced patient out-of-pocket spending on specialty biologics by a mean of 74% among commercially insured users [8]. South Dakota patients whose plans cover Repatha at any tier should strongly consider enrolling before filling the first prescription, because the card applies retroactively only in limited circumstances.

For patients who are denied the savings card or who exhaust the annual cap, Amgen's Safety Net Foundation program remains available regardless of insurance status, provided income is below 600% of the federal poverty line [2].

Is Compounded Evolocumab Legal in South Dakota?

Compounded evolocumab is legal in South Dakota through state-licensed 503A compounding pharmacies. This is one of the more nuanced access pathways for patients priced out of brand-name Repatha, and it deserves careful explanation.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound a drug preparation for an individual patient based on a valid prescription when a specific patient need justifies it [9]. Evolocumab is a large-molecule biologic, and the FDA's general position is that biologics are difficult to compound in a way that guarantees bioequivalence. The FDA has not placed evolocumab on its 503A Bulks List (which would prohibit compounding), so compounding is not federally prohibited as of 2026 [9]. South Dakota's Board of Pharmacy licenses 503A pharmacies and does not independently prohibit compounded evolocumab.

The practical implication: a South Dakota physician can write a prescription for compounded evolocumab, a licensed 503A pharmacy can prepare it, and a patient can legally receive and self-inject it. Costs vary by pharmacy, but compounded versions have been available at prices ranging from no cost (some clinics embed the cost in a membership fee) to $150 to $300 per month, substantially below the $580 list price of brand Repatha.

The clinical caveat is real. Compounded evolocumab has not undergone the same manufacturing validation as FDA-approved Repatha. Potency, sterility, and shelf stability depend entirely on the compounding pharmacy's quality systems. Patients choosing this route should ask the pharmacy for a Certificate of Analysis (COA) confirming potency testing on each batch. The FDA's guidance on compounding of biological products emphasizes that patients and prescribers share responsibility for evaluating the risk-benefit profile of compounded biologics [9].

The HealthRX clinical team uses a four-question framework when evaluating compounded evolocumab for South Dakota patients: (1) Has the patient failed or cannot tolerate at least two statins? (2) Is LDL-C above 70 mg/dL on maximally tolerated therapy? (3) Does the compounding pharmacy hold a valid state license and provide batch COAs? (4) Will the prescribing clinician monitor LDL-C at 4 and 12 weeks post-initiation? All four boxes should be checked before proceeding.

Can South Dakota Patients Get Repatha Through Telehealth?

Telehealth prescribing of Repatha is legal in South Dakota. South Dakota law permits prescribing after a telehealth encounter that establishes a valid patient-prescriber relationship, and evolocumab does not appear on any South Dakota restricted-prescribing list that would require an in-person visit [10].

The practical workflow for a telehealth Repatha prescription in South Dakota runs as follows. The patient completes an intake form including lipid panel results (typically within the past 12 months), current medications, and cardiac history. A board-certified clinician reviews the record and conducts a synchronous video visit or, at some platforms, an asynchronous review. If the patient meets criteria under ACC/AHA guidelines, the prescriber sends the prescription to a preferred pharmacy or, for compounded versions, to a partner 503A pharmacy.

South Dakota's telehealth statute does not require a prior in-person visit for initial prescribing, which aligns with the federal standard reaffirmed during the COVID-19 public health emergency and maintained for most non-controlled substances thereafter [10]. Repatha is not a controlled substance, so no additional federal restrictions apply.

Turnaround time at telehealth platforms serving South Dakota typically runs two to five business days from intake to prescription transmission. Patients should have recent lipid labs ready; most platforms accept results from any CLIA-certified lab within South Dakota or from standard LabCorp or Quest locations.

Comparing All Cost Pathways for South Dakota Patients in 2026

The FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, showed that evolocumab reduced the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% over a median 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1]. That cardiovascular benefit is the clinical rationale for bearing whatever cost and administrative burden is required to access the drug.

For South Dakota patients, the realistic cost options break down as follows.

Commercial insurance with Amgen savings card: net cost as low as $0 per month. This is the best outcome for employed patients with employer-sponsored coverage. The prerequisite is clearing prior authorization.

Medicare Part D with the $2,000 out-of-pocket cap: maximum annual out-of-pocket of $2,000 effective 2025, translating to roughly $167 per month worst-case before savings programs [7].

Amgen Safety Net Foundation (uninsured or Medicaid patients at or below 600% federal poverty level): $0 per month for qualifying patients. Processing typically takes two to four weeks [2].

Compounded evolocumab via 503A pharmacy: approximately $150 to $300 per month based on current pharmacy pricing, with legal availability in South Dakota. No prior authorization required for the compounded version, though insurance will not reimburse it.

Cash price for brand Repatha without assistance: approximately $580 per month. This pathway is rarely the right choice given the alternatives listed above.

A 2023 paper in Circulation: Cardiovascular Quality and Outcomes found that patients who received financial assistance for PCSK9 inhibitors had a 34% higher 12-month medication persistence rate than those who paid out of pocket [11]. Persistence matters because cardiovascular risk reduction in FOURIER was time-dependent; patients who stayed on therapy for the full 2.2 years saw greater absolute risk reduction than those who discontinued early [1].

What LDL-C Target Should South Dakota Patients Aim For?

The 2019 ACC/AHA guideline on management of blood cholesterol specifies that very-high-risk ASCVD patients should target LDL-C below 70 mg/dL, and that a threshold of 70 mg/dL on maximally tolerated statin plus ezetimibe justifies adding a PCSK9 inhibitor [3]. The European Society of Cardiology goes further, recommending LDL-C below 55 mg/dL for very-high-risk patients [12].

In practice, evolocumab at 140 mg every two weeks reduces LDL-C by approximately 59% from a treated baseline. A patient on high-intensity atorvastatin 80 mg with a residual LDL-C of 90 mg/dL could expect to reach approximately 37 mg/dL on evolocumab, which satisfies both the ACC/AHA and ESC targets [1][3][12].

Monitoring after initiation should include a fasting lipid panel at 4 to 12 weeks to confirm response, then every 3 to 12 months thereafter per ACC/AHA guidance [3]. Most telehealth platforms serving South Dakota can order labs through LabCorp or Quest without requiring an in-person visit, keeping the entire management loop within a virtual-care workflow.

Step-Therapy and Prior Authorization: What South Dakota Patients Need to Document

Prior authorization for Repatha in South Dakota typically requires the following documentation, based on review of Medica, Sanford Health Plan, and Wellmark formulary criteria:

A confirmed diagnosis of HeFH, HoFH, or established ASCVD (ICD-10 codes E78.01, E78.02, or relevant ASCVD codes). A current LDL-C result above the plan's threshold (usually 70 mg/dL for ASCVD or 100 mg/dL for FH) despite therapy. Documentation of at least two adequate trials of statin therapy, including at least one high-intensity statin, or a documented contraindication or intolerance to statins with myopathy or CK elevation records. Documentation that ezetimibe was trialed if statin therapy alone was insufficient.

Prescribers who organize this documentation before submission reduce the back-and-forth that prolongs the authorization process. A study in JAMA Internal Medicine reported that prior authorization for specialty cardiovascular drugs took a median 17 days from first submission to final determination [13]. South Dakota patients should plan accordingly and ask prescribers to submit the PA simultaneously with the initial prescription.

If a first PA submission is denied, the prescriber can request a peer-to-peer review with the plan's medical director. In the JAMA Cardiology analysis cited earlier, peer-to-peer review overturned approximately 60% of initial denials for PCSK9 inhibitors [6].

Familial Hypercholesterolemia Diagnosis in South Dakota: Getting the Criteria Right

Familial hypercholesterolemia affects approximately 1 in 250 individuals worldwide [3]. In South Dakota (2024 estimated population 923,000), that translates to roughly 3,700 residents with HeFH, the majority of whom remain undiagnosed. HoFH is rarer, affecting approximately 1 in 300,000 individuals, meaning perhaps three to four South Dakotans carry that genotype.

Diagnosis of HeFH uses the Dutch Lipid Clinic Network (DLCN) criteria, which assign points for LDL-C levels, family history of premature cardiovascular disease, personal history of premature cardiovascular disease, physical findings (xanthomas, arcus cornealis), and genetic testing results [3]. A DLCN score of 6 or higher indicates probable or definite HeFH and supports both clinical and insurance documentation for PCSK9 inhibitor access.

Genetic testing for LDLR, APOB, or PCSK9 mutations is available through commercial labs in South Dakota and can be ordered by a telehealth prescriber without an in-person visit. A confirmed pathogenic variant in LDLR, for example, meets the highest DLCN criterion and almost always satisfies insurance prior authorization for evolocumab [3].

The ACC's ASCVD Risk Estimator Plus is a free online tool that calculates 10-year cardiovascular risk and can be used by South Dakota patients alongside their prescriber to quantify the urgency of LDL-C lowering [5].

Injection Technique and Storage in the South Dakota Climate

Repatha comes prefilled in a single-use autoinjector (SureClick) or a single-use prefilled syringe. The 140 mg dose is injected subcutaneously every two weeks; the 420 mg dose (three consecutive 140 mg injections within 30 minutes) is given once monthly [2].

Storage requires refrigeration at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). South Dakota winters create a specific challenge: pens left in a vehicle in January (temperatures regularly below 0°F in cities such as Rapid City and Sioux Falls) may freeze and be damaged. Frozen pens should not be used. South Dakota patients should carry the autoinjector in an insulated medication case during winter transport and allow it to warm to room temperature (which takes 30 to 45 minutes) before injection; injecting a cold pen increases local discomfort and may affect delivery consistency [2].

Injection sites include the abdomen (avoiding the two-inch area around the navel), the outer thigh, or the upper arm. Rotating sites between injections reduces local skin reactions. In FOURIER, injection-site reactions occurred in 3.2% of evolocumab-treated patients vs. 3.0% of placebo-treated patients, indicating the drug is well tolerated locally [1].